CoChat

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index; 69 of the 118 sources its claims cite were checked for support.

Exposure to Per- and Polyfluoroalkyl Substances (PFASs) in Healthcare: Environmental and Clinical Insights

Open access

Abstract

Per- and polyfluoroalkyl substances (PFASs) are synthetic chemicals extensively used in various industries due to their unique physicochemical properties. Their persistence in the environment and potential for bioaccumulation have raised significant health concerns. This review aims to elucidate the sources, exposure pathways, toxicological effects, and regulatory measures related to PFASs, with a particular focus on pediatric populations and medical applications. A comprehensive narrative review was conducted using PubMed, Scopus, and Web of Science to identify peer-reviewed literature published between 2000 and 2025. The search focused on PFAS use in healthcare, environmental contamination, exposure pathways, health effects, and regulatory actions. Relevant studies, reports, and policy documents were screened and thematically synthesized by the authors to evaluate clinical and environmental risks, particularly in pediatric populations. PFAS exposure is linked to various adverse health effects, including immunotoxicity, endocrine disruption, metabolic disorders, and carcinogenicity. Children are particularly vulnerable due to developmental susceptibilities and exposure through medical devices and environmental sources. Regulatory measures are evolving, but gaps remain, especially concerning medical device applications. There is an urgent need for comprehensive strategies to monitor and mitigate PFAS exposure, particularly in vulnerable populations. Enhanced regulatory frameworks, safer alternatives in medical devices, and public health interventions are essential to address the challenges posed by PFASs.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence that PFAS exposure occurs through both environmental contamination and healthcare-related pathways, with children and intensive-care patients especially vulnerable. It highlights persistent toxicological risks—immunotoxicity, endocrine disruption, metabolic disease, and carcinogenicity—while noting major gaps in quantifying PFAS leaching from medical devices and regulating PFAS in medical products.

Key findings

  • Environmental contamination is widespread: a 2024 global survey of >45,000 surface and groundwater samples found ~31% exceeded PFAS thresholds harmful to human health; PFASs were detected in 45% of surveyed North American tap water sources, and the U.S. EPA indicated 70 million Americans receive drinking water with detectable PFASs. In Canada, nearly 69% of groundwater samples in regulated regions surpassed national PFAS thresholds, and biosolid-amended soils reached PFAS levels as high as 300 µg/kg.
  • Pediatric exposure is elevated: the CHARGE study reported median PFOS serum levels of 8.1 ng/mL (range 5.0–31.5) in children aged 2–5, exceeding maternal levels; Norwegian cohort data found about 20% of children under 12 exceeded current safety thresholds; a PBPK model estimated mean PFOS 7–12 ng/mL and PFOA 3–6 ng/mL in children aged 6–12.
  • Health effects include immunotoxicity, endocrine disruption, metabolic disruption, neurodevelopmental harm, and cancer: IARC Monograph 135 (2023) classifies PFOA as Group 1 and PFOS as Group 2B; prenatal PFOS, PFOA, and PFHxS were linked to 1.6–2.0 point reductions in boys’ performance IQ per log-unit increase; PFAS exposure was associated with reduced birth weight (up to 181 g per ng/mL increase in PFHpS).
  • Regulatory action is advancing but incomplete: the EU Drinking Water Directive sets 0.1 µg/L for the sum of 20 PFASs and 0.5 µg/L for total PFASs by January 12, 2026; the U.S. EPA set MCLs of 4 ppt for PFOA and PFOS and a cumulative hazard index of 1.0 for PFNA, PFHxS, PFBS, and GenX. However, specific regulations for PFASs in medical devices remain limited, and direct patient exposure from devices such as ECMO circuits and ICU tubing is largely unquantified.

Methods

  • Narrative review designed to synthesize evidence on PFAS exposure through environmental pathways relevant to child health and healthcare settings, particularly PICUs, NICUs, and general pediatric departments.
  • Literature search across PubMed, Scopus, and Web of Science for peer-reviewed publications from January 2000 to March 2025, plus gray literature from ECHA, U.S. EPA, and WHO; English-language publications only.
  • PRISMA-style screening: 2345 records retrieved, 422 duplicates removed, 1923 title/abstract screened, 1612 excluded, 311 full-text reviewed, and 152 publications included in a final qualitative synthesis organized into thematic sections.

Limitations

  • The paper states that direct measurement of PFAS exposure in patients on ECMO has not yet been reported, quantitative assessments of PFAS leaching from ICU tubing and other in-hospital devices are absent, and clinical exposure via medical devices remains largely unquantified.
  • The paper notes that proposed short-chain PFAS substitutes such as GenX remain under-investigated and may carry similar risks, and that regulatory frameworks are inconsistent and incomplete, especially for medical devices.
  • Evident from the text: as a narrative review with qualitative synthesis, it does not pool effect estimates or formally assess risk of bias; inclusion was limited to English-language literature and gray literature from selected agencies, which may introduce selection and language bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/life15071057

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA-style flowchart summarizing the study selection process.
Figure 1 PRISMA-style flowchart summarizing the study selection process.CC BY · PubMed Central
Figure 2 Environmental sources and pathways of exposure to PFASs.
Figure 2 Environmental sources and pathways of exposure to PFASs.CC BY · PubMed Central
Figure 3 Toxicological effects of PFASs exposure are associated with various adverse health outcomes. Vulnerable populations include children, pregnant women, and chronically ill subjects.
Figure 3 Toxicological effects of PFASs exposure are associated with various adverse health outcomes. Vulnerable populations include children, pregnant women, and chronically ill subjects.CC BY · PubMed Central
Figure 4 Strategies for monitoring and mitigation of PFAS exposure in pediatric patients.
Figure 4 Strategies for monitoring and mitigation of PFAS exposure in pediatric patients.CC BY · PubMed Central

Verification

Claims the paper makes

46 Valid · 10 Not valid · 33 Not checked · 15 Own results and interpretations

50 more claims · 25 with their cited sources checked

Create a free account to see all 104 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 126 references

Research works printed but not linked: 3

  1. Brandsch, 2022, Determination of PFAS in Water According to EU 2020/2184 and DIN 38407-42 Using Online SPE–LC–MS/MS, MJH Life Sci., 18, 8
  2. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Division on Earth and Life Studies, Board on Population Health and Public Health Practice, Board on Environmental Studies and Toxicology, and Committee on the Guidance on PFAS Testing and Health Outcomes (2022). Guidance on PFAS Exposure, Testing, and Clinical Follow-Up, National Academies Press (US). The National Academies Collection: Reports Funded by National Institutes of Health.
  3. IARC Working Group on the Identification of Carcinogenic Hazards to Humans (2025, June 19). Perfluorooctanoic Acid (PFOA) and Perfluorooctanesulfonic Acid (PFOS), Available online: http://www.ncbi.nlm.nih.gov/books/NBK614282/.

Cited by

See all 15

Metadata

Authors
Briassoulis, G., Ilia, S., & Briassouli, E.
Affiliations
  • University of Crete (GR)
  • National and Kapodistrian University of Athens (GR)
Corresponding author
Briassoulis, George
Venue
Life
Publisher
MDPI AG
Published
2025-07-01
Volume
15
Issue
7
Pages
1057
ISSN
2075-1729 (ISSN-L)
OpenAlex
W4411887479
Cited by
15
References
126
Citations by year
2026: 13 · 2025: 2
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • Life (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
  • Physical Sciences › Materials Science › Polymers and Plastics › Synthesis and properties of polymers
  • Physical Sciences › Chemistry › Organic Chemistry › Fluorine in Organic Chemistry
Keywords
per- and polyfluoroalkyl substances, PFAS exposure, health care, medical devices, children's exposure, immunotoxicity, endocrine disruption, carcinogenicity, metabolic disorders, environmental contamination, exposure pathways, PFAS regulation, safer alternatives, bioaccumulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exposure to Per- and Polyfluoroalkyl Substances (PFASs) in Healthcare: Environmental and Clinical Insights. https://app.cochat.ai/papers/10.3390/life15071057
The paper
Briassoulis, G., Ilia, S., & Briassouli, E. (2025). Exposure to Per- and Polyfluoroalkyl Substances (PFASs) in Healthcare: Environmental and Clinical Insights. Life. https://doi.org/10.3390/life15071057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.